Non-Small Cell Carcinoma — Research

Non-Small Cell Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	1,188	`("Non-Small Cell Carcinoma"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	218	`("Non-Small Cell Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	34	`("Non-Small Cell Carcinoma"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (372)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 226–250 of 372 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
· Cancer Res · 2010 · PMID 21030459 · validated civic_curation pubmed
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
· Cancer Discov · 2011 · PMID 22328973 · validated civic_curation pubmed
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
· Lung Cancer · 2014 · PMID 24636847 · validated civic_curation pubmed
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.